Skip to main content
Category

Investors

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

 May 8, 2024
May 8, 2024

Suspension of trading of Medincell shares, trading to resume tomorrow

 May 8, 2024
May 8, 2024

[Replay] Videoconference • Collaboration with AbbVie (French)

 April 17, 2024
April 17, 2024

Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies

 April 16, 2024
April 16, 2024

[Replay] Medincell Presentation at the 23rd Annual Needham Virtual Healthcare Conference

 April 11, 2024
April 11, 2024

Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

 April 8, 2024
April 8, 2024

MedinCell to present at the 23rd Annual Needham Virtual Healthcare Conference

 March 28, 2024
March 28, 2024

Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell’s Supervisory Board

 March 13, 2024
March 13, 2024

[Replay] Medincell Presentation at Evercore ISI 2024 Emerging Biotech Conference

 February 28, 2024
February 28, 2024